Bosutinib dosing
EVENTS
Core element of the study was the evaluation of the step-in dosing concept. The maximum duration of the dose optimization period was 3 months. If a patient was not able to enter the highest dose level of 500 mg at month 3, the current dose level was to be administered for the rest of the study (unless new side effects or events occurred that required dose reduction). All 57 pts started at day 1 with 300 mg bosutinib (QD). Thirty-four (60%) pts successfully completed the 2-weekly step-in dosing scheme and reached the targeted dose level of 500 mg QD (for distribution of pts among the different dosing levels at all visits until month 3, see Fig. Distribution of all 57 pts to different dosing levels of bosutinib from baseline until month 6; mg, milligram